Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.3.1399

Incremental Expression of 14-3-3 Protein Beta/Alpha in Urine Correlates with Advanced Stage and Poor Survival in Patients with Clear Cell Renal Cell Carcinoma  

Kaneko, Shiho (Department of Urology, Kitasato University School of Science)
Matsumoto, Kazumasa (Department of Urology, Kitasato University School of Science)
Minamida, Satoru (Department of Urology, Kitasato University School of Science)
Hirayama, Takahiro (Department of Urology, Kitasato University School of Science)
Fujita, Tetsuo (Department of Urology, Kitasato University School of Science)
Kodera, Yoshio (Department of Physics, Kitasato University School of Science)
Iwamura, Masatsugu (Department of Urology, Kitasato University School of Science)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.3, 2016 , pp. 1399-1404 More about this Journal
Abstract
We investigated the urinary levels of 14-3-3 protein beta/alpha to evaluate their diagnostic significance with regard to clear cell renal cell carcinoma (ccRCC) and angiomyolipoma (AML). Urine samples from 91 patients with ccRCC, 16 patients with AML and 24 healthy volunteers were assessed. We used an enzyme-linked immunosorbent assay (ELISA) to quantify 14-3-3 protein beta/alpha levels in urine. Values were higher in patients with ccRCC than in those with AML and in healthy volunteers. High levels were associated with pathologic stage, lymph node status, distant metastasis and poor survival. Urinary levels of 14-3-3 protein beta/alpha were significantly increased in patients with small-sized carcinoma, irrespective of being less than 4.0 cm and 2.0 cm, compared with levels in patients with AML. This study is the first to report that increased expression of 14-3-3 protein beta/alpha in urine is associated with advanced stage and poor survival in patients with ccRCC. In addition, urinary 14-3-3 protein beta/alpha may differentiate AML from RCC, even when small sized. These results suggest that examination of urinary 14-3-3 protein beta/alpha could serve as a diagnostic and prognostic marker in patients with ccRCC.
Keywords
14-3-3 protein beta/alpha; renal cell carcinoma; diagnosis; ELISA;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 Aitken A (1996). 14-3-3 and its possible role in co-ordinating multiple signaling pathways. Trends Cell Biol, 6, 341-7.   DOI
2 Amato RJ (2005). Renal cell carcinoma: review of novel single agent therapeutics and combination regimens. Ann Oncol, 16, 7-15.   DOI
3 Bissler JJ, Kingswood JC (2004). Renal angiomyolipomata. Kidney Int, 66, 924-34.   DOI
4 Frank I, Blute ML, Cheville JC, et al (2003). Solid renal tumors: an analysis of pathological features related to tumor size. J Urol, 170, 2217-20.   DOI
5 Fu H, Subramanian RR, Masters SC (2000). 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol, 40, 617-47.   DOI
6 Greene FL, Page DL, Fleming ID, et al (2002). AJCC Cancer Staging Manual, 6th edn. Springer, New York.
7 Jinzaki M, Tanimoto A, Narimatsu Y, et al (1997). Angiomyolipoma: imaging findings in lesions with minimal fat. Radiol, 205, 497-502.   DOI
8 Liou JY, Wu CC, Chen BR, et al (2008). Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-delta transcriptional pathway. Mol Pharmacol, 74, 1399-1406.   DOI
9 Lipworth L, Tarone RE, McLaughlin JK (2006). The epidemiology of renal cell carcinoma. J Urol, 176, 2353-8.   DOI
10 Liu TA, Jan YJ, Ko BS, et al (2011). Increased expression of 14-3-3 ${\beta}$ promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma. Am J Pathol, 179, 2698-708.   DOI
11 Lowrance WT, Ordonez J, Udaltsova N, et al (2014). CKD and the risk of incident cancer. J Am Soc Nephrol, 25, 2327-34   DOI
12 Masakazu W, Mitsuru M, Kazuya M, et al (2014). Risk Factors for Renal Cell Carcinoma in a Japanese Population. Asian Pac J Cancer Prev, 15, 9065-70.   DOI
13 Matsuura K, Nakada C, Mashio M, et al (2011). Downregulation of SAV1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. BMC Cancer, 11, 523-32.   DOI
14 Mhawech P (2005). 14-3-3 proteins-an update. Cell Res, 15, 228-236.   DOI
15 Ngo TC, Wood CG, Karam JA (2014). Biomarkers of renal cell carcinoma. Urol Oncol, 32, 243-51.   DOI
16 Morrison DK (2009). The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol, 19, 16-23.   DOI
17 Mues AC, Palacios JM, Haramis G, et al (2010). Contemporary experience in the management of angiomyolipoma. J Endourol, 24, 1883-6.   DOI
18 Musholt TJ, Brehm C, Hanack J, et al (2006). Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1. J Surg Res, 131, 15-25.   DOI
19 Nguyen MM, Gill IS, Ellison LM (2006). The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results Program. J Urol, 176, 2397-400.   DOI
20 Patil S, Ishill N, Deluca J, et al (2010). Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients. Cancer, 116, 347-54.   DOI
21 Qi W, Liu X, Qiao D, et al (2005). Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int J Cancer, 113, 359-63.   DOI
22 Satoru M, Masatsugu I, Yoshio K, et al (2011). 14-3-3 Protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid. Anal Bioanal Chem, 401, 245-52.   DOI
23 Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29.   DOI
24 Sugiyama A, Miyagi Y, Komiya Y, et al (2003). Forced expression of antisense14-3-3beta RNA suppresses tumor cell growth in vitro and in vivo. Carcinogenesis, 24, 1549-59.   DOI
25 Weiss RH, Lin PY (2006). Kidney cancer: identification of novel targets for therapy. Kidney Int, 69, 224-32.   DOI
26 Takihara Y, Matsuda Y, Hara J (2000). Role of the beta isoform of 14-3-3 proteins in cellular proliferation and oncogenic transformation. Carcinogenesis, 21, 2073-7.   DOI
27 Washio M, Mori M, Mikami K, et al (2013). Cigarette smoking and other risk factors for kidney cancer death in a Japanese population: Japan collaborative cohort Study for Evaluation of Cancer Risk (JACC study). Asian Pac J Cancer Prev, 14, 6523-8.   DOI
28 Wei C, Lai YQ, Li XX,Ye JX (2013). TGF-beta-activated kinase-1: a potential prognostic marker for clear cell renal cell carcinoma. Asian Pac J Cancer Prev, 14, 315-20.   DOI
29 Wen RM, Zhang YJ, Ma S, et al (2015). Preoperative neutrophil to lymphocyte ratio as a prognostic factor in patients with non-metastatic renal cell carcinoma. Asian Pac J Cancer Prev, 16, 3703-8.   DOI
30 Wu Q, Liu CZ, Tao LY, et al (2012). The clinicopathological and prognostic impact of 14-3-3 protein isoforms expression in human cholangiocarcinoma by immunohistochemistry. Asian Pac J Cancer Prev, 13, 1253-9.   DOI
31 Yang X, Cao W, Lin H, et al (2009). Isoform-specific expression of 14-3-3 proteins in human astrocytoma. J Neurol Sci, 276, 54-9.   DOI
32 Yu ZH, Zhang Q, Wang YD, et al (2013). Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma. Asian Pac J Cancer Prev, 14, 3729-4.   DOI
33 Zhao J, Meyerkord CL, Du Y, et al (2011). 14-3-3 proteins as potential therapeutic targets. Semin Cell Dev Biol, 22, 705-12.   DOI